IL160319A0 - Compositions and method of treating diabetes - Google Patents

Compositions and method of treating diabetes

Info

Publication number
IL160319A0
IL160319A0 IL16031902A IL16031902A IL160319A0 IL 160319 A0 IL160319 A0 IL 160319A0 IL 16031902 A IL16031902 A IL 16031902A IL 16031902 A IL16031902 A IL 16031902A IL 160319 A0 IL160319 A0 IL 160319A0
Authority
IL
Israel
Prior art keywords
compositions
treating diabetes
chimeric peptides
diabetes
treating
Prior art date
Application number
IL16031902A
Other languages
English (en)
Original Assignee
Diatos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diatos Sa filed Critical Diatos Sa
Publication of IL160319A0 publication Critical patent/IL160319A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL16031902A 2001-08-30 2002-08-30 Compositions and method of treating diabetes IL160319A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31606301P 2001-08-30 2001-08-30
US10/231,894 US7049286B2 (en) 2001-08-30 2002-08-29 Insulin conjugates and methods of use thereof
PCT/IB2002/003916 WO2003018636A2 (fr) 2001-08-30 2002-08-30 Compositions et procedes pour traiter le diabete

Publications (1)

Publication Number Publication Date
IL160319A0 true IL160319A0 (en) 2004-07-25

Family

ID=27668390

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16031902A IL160319A0 (en) 2001-08-30 2002-08-30 Compositions and method of treating diabetes

Country Status (14)

Country Link
US (2) US7049286B2 (fr)
EP (1) EP1427758B1 (fr)
JP (2) JP2005505266A (fr)
CN (1) CN1549826A (fr)
AT (1) ATE375999T1 (fr)
BR (1) BR0212203A (fr)
CA (1) CA2458866A1 (fr)
DE (1) DE60223058T2 (fr)
DK (1) DK1427758T3 (fr)
ES (1) ES2294195T3 (fr)
IL (1) IL160319A0 (fr)
NZ (1) NZ531101A (fr)
PT (1) PT1427758E (fr)
WO (1) WO2003018636A2 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003595B2 (en) * 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
US20040121309A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues
US20030027135A1 (en) 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
FR2841902A1 (fr) * 2002-07-08 2004-01-09 Diatos Peptides lineaires cationiques ayant des proprietes antibacteriennes et/ou antifongiques
JP2006516193A (ja) 2002-12-06 2006-06-29 アイシス・ファーマシューティカルス・インコーポレーテッド ヒトおよび動物における病原体の迅速な同定方法
US8046171B2 (en) 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
EP1512696A1 (fr) * 2003-08-14 2005-03-09 Diatos Séquences d'acides aminés facilitant la pénétration d'une substance d'intérêt dans les cellules et/ou le noyau
ATE533786T1 (de) * 2003-08-14 2011-12-15 Cellectis Aminosäuresequenzen, die das eindringen einer substanz von interesse in zellen und/oder zellkerne erleichtern
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US20120122099A1 (en) 2003-09-11 2012-05-17 Rangarajan Sampath Compositions for use in identification of bacteria
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
ES2641832T3 (es) 2004-05-24 2017-11-14 Ibis Biosciences, Inc. Espectrometría de masas con filtración de iones selectiva por establecimiento de umbrales digitales
US20050266411A1 (en) 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
US8182992B2 (en) 2005-03-03 2012-05-22 Ibis Biosciences, Inc. Compositions for use in identification of adventitious viruses
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
JP2009502137A (ja) 2005-07-21 2009-01-29 アイシス ファーマシューティカルズ インコーポレイティッド 核酸変種の迅速な同定および定量のための方法
EP1818395A1 (fr) * 2006-02-08 2007-08-15 Diatos Compositions et méthodes pour le traitement de maladies lysosomales
US8410045B2 (en) 2006-03-30 2013-04-02 Drais Pharmaceuticals, Inc. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
EP2064332B1 (fr) 2006-09-14 2012-07-18 Ibis Biosciences, Inc. Procédé d'amplification ciblée de génome entier pour l'identification d'agents pathogènes
EP2126132B1 (fr) 2007-02-23 2013-03-20 Ibis Biosciences, Inc. Procédé d'analyse d'adn médico-légale rapide
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
WO2010033625A1 (fr) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Systèmes de manipulation de microplaques et produits-programmes informatiques et procédés connexes
WO2010033599A2 (fr) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Cartouches de mélange, postes de mélange et kits, systèmes et procédés associés
US8158936B2 (en) 2009-02-12 2012-04-17 Ibis Biosciences, Inc. Ionization probe assemblies
WO2011008971A1 (fr) 2009-07-17 2011-01-20 Ibis Biosciences, Inc. Appareil de levage et de montage
WO2011008972A1 (fr) 2009-07-17 2011-01-20 Ibis Biosciences, Inc. Systèmes pour l'identification d'un bioagent
EP3225695A1 (fr) 2009-10-15 2017-10-04 Ibis Biosciences, Inc. Amplification de déplacement multiple
AU2011219716A1 (en) 2010-02-26 2012-09-27 Cellectis Use of endonucleases for inserting transgenes into safe harbor loci
JP6200806B2 (ja) * 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
WO2012015692A2 (fr) 2010-07-28 2012-02-02 Smartcells, Inc. Polypeptides d'insuline exprimés de façon recombinante et utilisations de ceux-ci
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
GB201322396D0 (en) 2013-12-18 2014-02-05 Univ Nottingham Transduction
US10232020B2 (en) * 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
CA3000742A1 (fr) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Proteines therapeutiques bispecifiques pour la reparation de tissus
US10717994B2 (en) * 2016-12-15 2020-07-21 Agricultural Technology Research Institute Recombinant polypeptide for enhancing cell transduction efficiency of a target agent
JP2021525261A (ja) * 2018-05-24 2021-09-24 アモライト・ファルマ 代謝疾患の治療におけるｉｇｆｂｐ−２のヘパリン結合ドメイン
MX2023007788A (es) 2021-01-24 2023-11-17 Michael David Forrest Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
CA2199005A1 (fr) 1994-09-01 1996-03-07 Emile Bourland (Deceased) Compositions et procedes d'administration de polypeptides
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
FR2736642B1 (fr) 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
US6066485A (en) * 1996-03-21 2000-05-23 New York University Growth factor inducible serine/threonine phosphatase fin13
US6068993A (en) * 1997-07-02 2000-05-30 Biobras Sa Vector for expression of heterologous protein and methods for extracting recombinant protein and for purifying isolated recombinant insulin
FR2766826B1 (fr) 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
CA2318355A1 (fr) 1997-12-23 1999-07-01 Alexion Pharmaceuticals, Inc. Proteines chimeres pour le traitement du diabete
WO2000045831A1 (fr) 1999-02-02 2000-08-10 Thomas Jefferson University Activites de modulation des peptides de l'heparine, et d'autres glycosaminoglycanes ou proteoglycanes
US6855801B1 (en) * 1999-02-02 2005-02-15 Thomas Jefferson University Peptides modulating activities of heparin other glycosaminoglycans or proteoglycans
FR2805821B1 (fr) 2000-03-01 2004-01-16 Diatos Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires

Also Published As

Publication number Publication date
CA2458866A1 (fr) 2003-03-06
DE60223058D1 (de) 2007-11-29
JP2005505266A (ja) 2005-02-24
US20060166889A1 (en) 2006-07-27
CN1549826A (zh) 2004-11-24
ATE375999T1 (de) 2007-11-15
ES2294195T3 (es) 2008-04-01
US20030153490A1 (en) 2003-08-14
EP1427758A2 (fr) 2004-06-16
DK1427758T3 (da) 2008-02-25
DE60223058T2 (de) 2008-07-24
US7112562B2 (en) 2006-09-26
US7049286B2 (en) 2006-05-23
JP2008271970A (ja) 2008-11-13
EP1427758B1 (fr) 2007-10-17
WO2003018636A3 (fr) 2003-11-27
NZ531101A (en) 2005-05-27
WO2003018636A2 (fr) 2003-03-06
PT1427758E (pt) 2008-01-22
BR0212203A (pt) 2004-09-21

Similar Documents

Publication Publication Date Title
IL160319A0 (en) Compositions and method of treating diabetes
MY142777A (en) Substituted indole-o-glucosides
UA87991C2 (en) Substituted indole-o-glucosides
TW200736277A (en) RANKL antibody-PTH/PTHrP chimeric molecules
WO2003053339A3 (fr) Molecule d'insuline a duree d'action prolongee
IL172674A0 (en) Isoforms of brain natriuretic peptide
MXPA03007983A (es) Procedimiento para la preparacion de destilados intermedios.
WO2006048777A3 (fr) Hormones de croissance modifiees
SI1629011T1 (sl) Humane molekule za vezavo anti hu cd
HK1099031A1 (en) Method for purifying fsh fsh
EP1215173A4 (fr) Compose 12cao . 7al203 provoquant la clathration d'especes d'oxygene actif et procede de preparation correspondant
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
MX2008012748A (es) Un proceso para la concentracion de un polipeptido.
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
WO2004048517A3 (fr) Procede pour reduire ou prevenir la modification d'un peptide dans une solution
AU2001258316A1 (en) Process for the fermentative preparation of l-threonine
AU3578002A (en) Flavour concentrates
MXPA03001468A (es) Polipeptidos de claudia.
UA83203C2 (uk) Тіазол-(бі)циклоалкілкарбоксаніліди, засіб на їх основі та застосування для боротьби з небажаними мікроорганізмами
WO2003094933A3 (fr) Methode de traitement utilisant des composes de lanthane
MXPA04002103A (es) Una proteina de union a caspasa-8, su preparacion y uso.
WO2005062893A3 (fr) Traitement anticorps anti-cd52 pour diabetes
HU0000531D0 (en) Method for the correction of deuteranopia, filter used by the method and procedure for the production of the filter
GB9726630D0 (en) Kv2.1 Antagonists
RS20060323A (en) Substituted indole-o-glucosides